Ensysce Biosciences (ENSC) Current Assets (2017 - 2025)

Ensysce Biosciences (ENSC) has reported Current Assets for 9 consecutive years, with $7.2 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Current Assets rose 35.56% year-over-year to $7.2 million in Q4 2025; TTM through Dec 2025 was $7.2 million, a 35.56% increase from a year earlier, with the FY2025 full-year figure at $7.2 million, up 35.56% from the prior year.
• Current Assets was $7.2 million for Q4 2025 at Ensysce Biosciences, up from $2.9 million in the prior quarter.
• Over five years, Current Assets peaked at $15.7 million in Q4 2021 and troughed at $228213.0 in Q1 2021.
• A 5-year average of $6.0 million and a median of $5.3 million in 2022 frame the typical range for Current Assets.
• Across the five-year window, Current Assets soared 8662.1% in 2021 and sank 71.09% in 2023, its largest moves.
• Over 5 years, Current Assets stood at $15.7 million in 2021, then plunged by 66.17% to $5.3 million in 2022, then tumbled by 56.81% to $2.3 million in 2023, then soared by 133.51% to $5.3 million in 2024, then jumped by 35.56% to $7.2 million in 2025.
• The last three Current Assets figures came in at $7.2 million (Q4 2025), $2.9 million (Q3 2025), and $5.3 million (Q2 2025), per Business Quant data.